Not sure if you've met Leo in person. I haven't, but I've talked to him and know a couple people close to him. I doubt VERY seriously if he'd sell anything short of its fullest potential. That's exactly the whole purpose of the current trial set. Brilacidin is more of a platform but partnering for individual indications is viable and very possible. Prurisol would be the one to sell/partner with royalties of course or fund with major bucks on milestones.
Read what he's saying in the 10-Q and the update, no partnership right away or in a fair amount of time once data from any of these trials is fully published (NOT just top line, though it could happen from just top line data) then I believe Leo will go the more dilutive route to get phase 3's rolling if only on the one that has the biggest impact.
My interpretation.
(3)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links